Earnings Insights: Verastem Oncology Gears Up for a Transformational Year with FDA Approval and Expanding Pipeline Verastem Oncology is entering a pivotal phase in 2025 as it builds on clinical momentum, secures a major regulatory milestone, and strengthens its financial pos

#VSTM kicks off 2025 with FDA approval, a major KRAS G12D licensing deal, and a strong cash position. Next stop: ASCO data drops and global trial momentum.
#VerastemOncolog
prismmarketview.com/earnings-ins...